Recent Development in Cardiovascular Pharmacogenomics

(2003-2005)

● Cardiovascular pharmacogenomics.

Johnson JA, Cavallari LH.
Exp Physiol. 2005 Mar 18.

● Pharmacogenomics in cardiovascular clinical trials.

Shah R, Darne B, Atar D, Abadie E, Adams KF, Zannad F; 5th Cardiovascular Clinical Trialists Workshop.
Fundam Clin Pharmacol. 2004 Dec;18(6):705-8.

● Pharmacogenomics.

Ross JS, Schenkein DP, Kashala O, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN.
Adv Anat Pathol. 2004 Jul;11(4):211-20.

● Cardiovascular pharmacogenomics.

Roden DM.
Circulation. 2003 Dec 23;108(25):3071-4.

● Race and medicine.

Holden C.
Science. 2003 Oct 24;302(5645):594-6.

● Zebrafish: a new model on the pharmaceutical catwalk.

Langheinrich U.
Bioessays. 2003 Sep;25(9):904-12.

● Cardiovascular pharmacogenetics in the SNP era.

Mooser V, Waterworth DM, Isenhour T, Middleton L.
J Thromb Haemost. 2003 Jul;1(7):1398-402.

● Pharmacogenomics of drugs affecting the cardiovascular system.

Siest G, Ferrari L, Accaoui MJ, Batt AM, Visvikis S.
Clin Chem Lab Med. 2003 Apr;41(4):590-9.

● Cardiovascular pharmacogenomics: current status, future prospects.

Anderson JL, Carlquist JF, Horne BD, Muhlestein JB.
J Cardiovasc Pharmacol Ther. 2003 Mar;8(1):71-83.

● Cardiovascular pharmacogenetics: on the way toward individually tailored drug therapy.

Siffert W.
Kidney Int Suppl. 2003 May;(84):S168-71.

● Pharmacogenomics in cardiovascular diseases.

Mukherjee D, Topol EJ.
Curr Probl Cardiol. 2003 May;28(5):317-47.

● Genetics and heart disease.

Chamsi Pasha H.
Saudi Med J. 2003 Jan;24(1):11-8.

Cardiovascular Pharmacogenomics-Specific Diseases

● Genetic determinants of platelet function in thromboembolic diseases.

Corral J, Gonzalez-Conejero R, Vicente V.
J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):166-71.

● Pharmacogenetic considerations in diseases of cardiac ion channels.

Anantharam A, Markowitz SM, Abbott GW.
J Pharmacol Exp Ther. 2003 Dec;307(3):831-8.

Heart Failure

● Pharmacogenomics of heart failure -- focus on drug disposition and action.

Cascorbi I, Paul M, Kroemer HK.
Cardiovasc Res. 2004 Oct 1;64(1):32-9.

● Pharmacogenomics of congestive heart failure.

Baliga RR, Narula J.
Med Clin North Am. 2003 Mar;87(2):569-78, xiv.

Hypertension Pharmacogenomics and Drug Responses

● A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide.

Maitland-van der Zee AH, Turner ST, Schwartz GL, Chapman AB, Klungel OH, Boerwinkle E.
Pharmacogenet Genomics. 2005 May;15(5):287-293.

● Antihypertensive pharmacogenetics.

Nogueira JB.
Rev Port Cardiol. 2004 Dec;23(12):1621-30.

● Pharmacogenomics of left ventricular hypertrophy reversal: beyond the 'one size fits all' approach to antihypertensive therapy.

Schillaci G.
J Hypertens. 2004 Dec;22(12):2273-5.

● Drug-gene interactions between genetic polymorphisms and antihypertensive therapy.

Schelleman H, Stricker BH, De Boer A, Kroon AA, Verschuren MW, Van Duijn CM, Psaty BM, Klungel OH.
Drugs. 2004;64(16):1801-16.

● The shift in the "paradigm" of the pharmacology of hypertension.

Flordellis CS, Goumenos D, Kourounis G, Tsementzis SA, Paris H, Vlachojiannis J.
Curr Top Med Chem. 2004;4(4):487-98.

● Trends in pharmacogenomics of drugs acting on hypertension.

Trotta R, Donati MB, Iacoviello L.
Pharmacol Res. 2004 Apr;49(4):351-6.

● Pharmacogenetics of hypertension treatment: a structured review.

Koopmans RP, Insel PA, Michel MC.
Pharmacogenetics. 2003 Dec;13(12):705-13.

● Emerging drugs in the management of hypertension.

Whitworth JA.
Expert Opin Emerg Drugs. 2003 Nov;8(2):377-88.

● Genetic epidemiology of hypertension: an update on the African diaspora.

Daniel HI, Rotimi CN.
Ethn Dis. 2003 Summer;13(2 Suppl 2):S53-66.

● Gender-specific genetic determinants of blood pressure and organ weight: pharmacogenetic approach.

Ueno T, Tremblay J, Kunes J, Zicha J, Dobesova Z, Pausova Z, Deng AY, Sun Y, Jacob HJ, Hamet P.
Physiol Res. 2003;52(6):689-700.

● Pharmacogenomics of primary hypertension--the lessons from the past to look toward the future.

Bianchi G, Staessen JA, Patrizia F.
Pharmacogenomics. 2003 May;4(3):279-96.

● Genes and hypertension.

Garcia EA, Newhouse S, Caulfield MJ, Munroe PB.
Curr Pharm Des. 2003;9(21):1679-89.

● Pharmacogenomics of hypertension.

Cadman PE, O'Connor DT.
Curr Opin Nephrol Hypertens. 2003 Jan;12(1):61-70.

Antihypertensive Drug Responses

● Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment.

Liljedahl U, Kahan T, Malmqvist K, Melhus H, Syvanen AC, Lind L, Kurland L.
J Hypertens. 2004 Dec;22(12):2321-8.

● Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment.

Liljedahl U, Lind L, Kurland L, Berglund L, Kahan T, Syvanen AC.
BMC Cardiovasc Disord. 2004 Sep 28;4(1):16.

● Pharmacogenetics of antihypertensive drug responses.

Schwartz GL, Turner ST.
Am J Pharmacogenomics. 2004;4(3):151-60.

● Pharmacogenetics of antihypertensive drug response.

Kreutz R.
Curr Hypertens Rep. 2004 Feb;6(1):15-20.

● The antihypertensive response to irbesartan treatment from a pharmacogenetic perspective.

Kurland L.
Minerva Med. 2003 Aug;94(4):251-8.

● A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response.

Liljedahl U, Karlsson J, Melhus H, Kurland L, Lindersson M, Kahan T, Nystrom F, Lind L, Syvanen AC.
Pharmacogenetics. 2003 Jan;13(1):7-17.

Cardiovascular Pharmacogenomics – Specific Drugs and Drug Responses

● Pharmacogenetics of response to statins: where do we stand?

Maitland-van der Zee AH, Boerwinkle E.
Curr Atheroscler Rep. 2005 May;7(3):204-8.

● Sequencing drug response with HapMap.

Lin M, Aquilante C, Johnson JA, Wu R.
Pharmacogenomics J. 2005 Mar 22.

● The emerging pharmacogenomics of the beta-adrenergic receptors.

Taylor MR, Bristow MR.
Congest Heart Fail. 2004 Nov-Dec;10(6):281-8.

● The role of atypical antipsychotics in glucose/insulin dysregulation and the evolving role of the psychiatrist in a new era of drug treatment options.

Ferraioli A, Shirley KL, David P.
CNS Spectr. 2004 Nov;9(11):849-61.

● Pharmacogenomics and drug response in cardiovascular disorders.

Siest G, Jeannesson E, Berrahmoune H, Maumus S, Marteau JB, Mohr S, Visvikis S.
Pharmacogenomics. 2004 Oct;5(7):779-802.

● Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype.

Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, Burmester JK.
Pharmacogenetics. 2004 Aug;14(8):539-47.

● Pharmacogenetics as related to the practice of cardiothoracic and vascular anesthesia.

Bukaveckas BL, Valdes R Jr, Linder MW.
J Cardiothorac Vasc Anesth. 2004 Jun;18(3):353-65.

● Dexamethasone lacks effect on blood pressure in mice with a disrupted endothelial NO synthase gene.

Wallerath T, Godecke A, Molojavyi A, Li H, Schrader J, Forstermann U.
Nitric Oxide. 2004 Feb;10(1):36-41.

● Pharmacogenetics of paraoxonases: a brief review.

Draganov DI, La Du BN.
Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):78-88.

● Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol.

Liu J, Liu ZQ, Tan ZR, Chen XP, Wang LS, Zhou G, Zhou HH.
Clin Pharmacol Ther. 2003 Oct;74(4):372-9.

● Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy.

Schmitz G, Drobnik W.
Clin Chem Lab Med. 2003 Apr;41(4):581-9.

● Antiarrhythmic drugs: new agents and evolving concepts.

Nemec J, Shen WK.
Expert Opin Investig Drugs. 2003 Mar;12(3):435-53.